New York State Common Retirement Fund
KPTI icon

New York State Common Retirement Fund’s Karyopharm Therapeutics KPTI Stock Holding History

New York State Common Retirement Fund’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-64
Closed -$829 – 3278
2024
Q2 		$829 Sell
64
-1,346
-95% -$22.3K ﹤0.01% 3296
2024
Q1 		$31.9K Buy
1,410
+118
+9% +$2.07K ﹤0.01% 3078
2023
Q4 		$16.8K Sell
1,292
-19
-1% -$256 ﹤0.01% 3166
2023
Q3 		$26.3K Buy
1,311
+47
+4% +$1.05K ﹤0.01% 3154
2023
Q2 		$33.9K Sell
1,264
-8
-0.6% -$345 ﹤0.01% 3194
2023
Q1 		$74.2K Sell
1,272
-2,000
-61% -$98.7K ﹤0.01% 2895
2022
Q4 		$167K Sell
3,272
-1,222
-27% -$84.7K ﹤0.01% 2799
2022
Q3 		$368K Buy
4,494
+1,236
+38% +$92.3K ﹤0.01% 2493
2022
Q2 		$220K Sell
3,258
-237
-7% -$21.7K ﹤0.01% 2757
2022
Q1 		$386K Buy
3,495
+655
+23% +$81.6K ﹤0.01% 2513
2021
Q4 		$274K Sell
2,840
-11
-0.4% -$1.1K ﹤0.01% 2753
2021
Q3 		$249K Sell
2,851
-1,102
-28% -$114K ﹤0.01% 2831
2021
Q2 		$612K Sell
3,953
-1,039
-21% -$151K ﹤0.01% 2487
2021
Q1 		$788K Sell
4,992
-366
-7% -$77.1K ﹤0.01% 2226
2020
Q4 		$1.24M Hold
5,358
– – ﹤0.01% 1941
2020
Q3 		$1.17M Sell
5,358
-429
-7% -$105K ﹤0.01% 1832
2020
Q2 		$1.64M Buy
5,787
+1,725
+42% +$510K ﹤0.01% 1614
2020
Q1 		$1.17M Hold
4,062
– – ﹤0.01% 1655
2019
Q4 		$1.17M Buy
4,062
+122
+3% +$26.5K ﹤0.01% 1881
2019
Q3 		$569K Buy
3,940
+973
+33% +$132K ﹤0.01% 2264
2019
Q2 		$267K Hold
2,967
– – ﹤0.01% 2678
2019
Q1 		$260K Hold
2,967
– – ﹤0.01% 2598
2018
Q4 		$417K Sell
2,967
-626
-17% -$106K ﹤0.01% 2366
2018
Q3 		$918K Hold
3,593
– – ﹤0.01% 2137
2018
Q2 		$916K Buy
3,593
+1,080
+43% +$267K ﹤0.01% 2147
2018
Q1 		$506K Buy
2,513
+480
+24% +$95.7K ﹤0.01% 2347
2017
Q4 		$293K Hold
2,033
– – ﹤0.01% 2594
2017
Q3 		$335K Buy
2,033
+153
+8% +$21.9K ﹤0.01% 2555
2017
Q2 		$255K Buy
1,880
+473
+34% +$70K ﹤0.01% 2723
2017
Q1 		$271K Sell
1,407
-555
-28% -$89.1K ﹤0.01% 2650
2016
Q4 		$277K Sell
1,962
-484
-20% -$65.4K ﹤0.01% 2650
2016
Q3 		$357K Sell
2,446
-18
-0.7% -$2.16K ﹤0.01% 2491
2016
Q2 		$248K Sell
2,464
-2,951
-54% -$383K ﹤0.01% 2628
2016
Q1 		$725K Hold
5,415
– – ﹤0.01% 2098
2015
Q4 		$1.08M Hold
5,415
– – ﹤0.01% 1926
2015
Q3 		$855K Buy
5,415
+602
+13% +$161K ﹤0.01% 2036
2015
Q2 		$1.96M Buy
+4,813
New +$2.08M ﹤0.01% 1863

Other funds holding KPTI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

New York State Common Retirement Fund's KPTI Position: Q3 2024 in Review

New York State Common Retirement Fund sold out of Karyopharm Therapeutics (KPTI) in Q3 2024, closing a stake of 64 shares — an estimated $829 sold.

New York State Common Retirement Fund first reported a position in KPTI in Q2 2015 and held it in 37 quarters. The position peaked at $1.96M in Q2 2015. 91 funds tracked by Wall St. Rank hold KPTI as of Q3 2024.

  • New York State Common Retirement Fund reported no remaining Karyopharm Therapeutics position as of Q3 2024 after selling out during the quarter.
  • New York State Common Retirement Fund sold 64 Karyopharm Therapeutics shares in Q3 2024, an estimated $829.
  • New York State Common Retirement Fund first reported a position in Karyopharm Therapeutics in Q2 2015 and held it in 37 quarters.
  • New York State Common Retirement Fund's Karyopharm Therapeutics position peaked at $1.96M in Q2 2015.
  • 91 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q3 2024.

Based on New York State Common Retirement Fund's 13F filing for Q3 2024, filed 28 Oct 2024.